BACKGROUND: The number of effective cytotoxic agents for the treatment of patients with metastatic soft tissue sarcoma (STS) is limited, especially when patients have failed anthracyline-based chemotherapy. PATIENTS AND METHODS: Between 1999 and 2000 a total of 16 patients with histologically proven STS progressing during or after first-line anthracycline-based chemotherapy were entered into this open-label, noncomparative study. Topotecan was administered as a 30-min infusion at a dosage of 1.5 mg/m(2) on five consecutive days every 3 weeks. All patients had received an anthracycline- or ifosfamide-based first-line chemotherapy. RESULTS: None of the 16 included patients achieved an objective response to topotecan. Six patients achieved stable disease (38%), lasting for at least 6 weeks in four patients (25%) and for less than 6 weeks in two patients (13%). Ten patients (62%) had progressive disease. The median time to progression was 79 days calculated from the start of topotecan therapy (range, 28-230). The treatment was well tolerated; however, both anemia and thrombopenia grade III/IV occurred in 25% of the patients as well as severe neutropenia in 69% of the patients. Nonhematologic toxicities grade III/IV such as diarrhea and severe bleeding occurred only in one patient each (6%). DISCUSSION: Topotecan is well tolerated in anthracycline-resistant patients with metastatic STS, but no objective response has been observed in this trial.
BACKGROUND: The number of effective cytotoxic agents for the treatment of patients with metastatic soft tissue sarcoma (STS) is limited, especially when patients have failed anthracyline-based chemotherapy. PATIENTS AND METHODS: Between 1999 and 2000 a total of 16 patients with histologically proven STS progressing during or after first-line anthracycline-based chemotherapy were entered into this open-label, noncomparative study. Topotecan was administered as a 30-min infusion at a dosage of 1.5 mg/m(2) on five consecutive days every 3 weeks. All patients had received an anthracycline- or ifosfamide-based first-line chemotherapy. RESULTS: None of the 16 included patients achieved an objective response to topotecan. Six patients achieved stable disease (38%), lasting for at least 6 weeks in four patients (25%) and for less than 6 weeks in two patients (13%). Ten patients (62%) had progressive disease. The median time to progression was 79 days calculated from the start of topotecan therapy (range, 28-230). The treatment was well tolerated; however, both anemia and thrombopenia grade III/IV occurred in 25% of the patients as well as severe neutropenia in 69% of the patients. Nonhematologic toxicities grade III/IV such as diarrhea and severe bleeding occurred only in one patient each (6%). DISCUSSION: Topotecan is well tolerated in anthracycline-resistant patients with metastatic STS, but no objective response has been observed in this trial.
Authors: S Delaloge; A Yovine; A Taamma; M Riofrio; E Brain; E Raymond; P Cottu; F Goldwasser; J Jimeno; J L Misset; M Marty; E Cvitkovic Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: R B Raney; J R Anderson; F G Barr; S S Donaldson; A S Pappo; S J Qualman; E S Wiener; H M Maurer; W M Crist Journal: J Pediatr Hematol Oncol Date: 2001-05 Impact factor: 1.289
Authors: S Frustaci; A Buonadonna; E Galligioni; D Favaro; A De Paoli; G Lo Re; R Sorio; S Tumolo; S Monfardini Journal: J Clin Oncol Date: 1997-04 Impact factor: 44.544
Authors: G Thomas Budd; Cathryn Rankin; Laura F Hutchins; Lucas Wong; Paul J Petruska; Karen Antman Journal: Invest New Drugs Date: 2002-02 Impact factor: 3.850
Authors: L Svancárová; J Y Blay; I R Judson; Q G C M van Hoesel; A T van Oosterom; A le Cesne; H J Keizer; C Hermans; M van Glabbeke; J Verweij; P C W Hogendoorn; O S Nielsen Journal: Eur J Cancer Date: 2002-03 Impact factor: 9.162
Authors: S O'Reilly; E K Rowinsky; W Slichenmyer; R C Donehower; A A Forastiere; D S Ettinger; T L Chen; S Sartorius; L B Grochow Journal: J Clin Oncol Date: 1996-12 Impact factor: 44.544
Authors: Jörg Thomas Hartmann; R D Issels; K San Nicolo; V Grünwald; B Hertenstein; E Papesch; S Krause; I Sturm Journal: Invest New Drugs Date: 2015-07-12 Impact factor: 3.850
Authors: M Lehnhardt; A Daigeler; H H Homann; J Hauser; S Langer; L Steinsträsser; C Soimaru; A Puls; H U Steinau Journal: Chirurg Date: 2009-04 Impact factor: 0.955
Authors: J T Hartmann; K Oechsle; J Huober; A Jakob; M Azemar; M Horger; L Kanz; C Bokemeyer Journal: Invest New Drugs Date: 2006-05 Impact factor: 3.651
Authors: Brian Schulte; Nisha Mohindra; Mohammed Milhem; Steven Attia; Steven Robinson; Varun Monga; Angela C Hirbe; Peter Oppelt; John Charlson; Irene Helenowski; Susan Abbinanti; Rasima Cehic; Scott Okuno; Brian A Van Tine; Mark Agulnik Journal: Br J Cancer Date: 2021-05-28 Impact factor: 9.075
Authors: Marcus Lehnhardt; Thomas Muehlberger; Cornelius Kuhnen; Daniel Brett; Hans U Steinau; Hamid Joneidi Jafari; Lars Steinstraesser; Oliver Müller; Heinz H Homann Journal: World J Surg Oncol Date: 2005-04-18 Impact factor: 2.754